Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sumatriptan fast-disintegrating/rapid-release tablets.

Marit D Moen1, Gillian M Keating

  • 1Adis International Limited, 41 Centorian Drive, Mairangi Bay, Auckland 1311, New Zealand. demail@adis.co.nz

Drugs
|May 19, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same author

Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same author

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.

Drugs·2017
Same author

Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

Drugs·2017
Same author

Sorafenib: A Review in Hepatocellular Carcinoma.

Targeted oncology·2017
Same author

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex<sup>®</sup>): A Review in Multiple Sclerosis-Related Spasticity.

Drugs·2017
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

A new fast-disintegrating sumatriptan tablet (FDT/RRT) offers faster migraine relief compared to standard tablets. This new formulation provides quicker pain freedom and improved tolerability for migraine attack treatment.

Area of Science:

  • Neurology
  • Pharmacology
  • Gastroenterology

Background:

  • Sumatriptan is a key serotonin 5-HT(1B/1D) receptor agonist for acute migraine treatment.
  • Standard sumatriptan tablets have limitations in absorption and onset of action.
  • A novel fast-disintegrating/rapid-release (FDT/RRT) sumatriptan tablet formulation has been developed.

Purpose of the Study:

  • To evaluate the bioequivalence of the new sumatriptan FDT/RRT tablets compared to standard sumatriptan tablets.
  • To assess the efficacy and onset of action of sumatriptan FDT/RRT in patients with mild, moderate, and severe migraine attacks.
  • To determine the tolerability profile of the sumatriptan FDT/RRT formulation.

Main Methods:

  • Bioequivalence study in healthy volunteers.

Related Experiment Videos

  • Randomized, double-blind, placebo-controlled trials in adult migraine patients (mild, moderate, and severe).
  • Assessment of pain freedom, migraine freedom, and time to pain relief as primary endpoints.

    • Main Results:

    • Sumatriptan FDT/RRT demonstrated bioequivalence to standard sumatriptan tablets.
    • Faster disintegration and gastric emptying observed with sumatriptan FDT/RRT.
    • Significantly more patients achieved pain-free or migraine-free status at 2 hours with sumatriptan FDT/RRT compared to placebo.
    • Statistically significant earlier pain relief observed with sumatriptan FDT/RRT (50mg and 100mg) compared to placebo in moderate to severe migraine trials.

    Conclusions:

    • Sumatriptan FDT/RRT offers a faster onset of action for migraine relief.
    • The new formulation is bioequivalent and generally well-tolerated, similar to standard sumatriptan tablets.
    • Sumatriptan FDT/RRT represents a promising advancement for the acute treatment of migraine attacks.